Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00624442 · ClinicalTrials.gov registry record · Phase 2

A Study of CK-1827452 Infusion in Stable Heart Failure

A Phase 2 study, sponsored by Cytokinetics.

Completed
Registry status
Phase 2
Development phase
45
Enrollment target

NCT00624442: Completed Phase 2 study, sponsored by Cytokinetics.

NCT00624442 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00624442, a Phase 2 study, has completed, sponsored by Cytokinetics.

COMPLETED
Registry status
Phase 2
Development phase
45 participants
Enrollment target

Study Summary

This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure.

Primary Outcome

Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.

Interventions

  • DRUG CK-1827452

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-04
Est. Completion 2009-02
Phase Phase 2
Cytokinetics

31 total trials

What the finished NCT00624442 record still lists

NCT00624442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).

The record links to 0 conditions, and to 1 intervention - of which CK-1827452 is the first listed.

NCT00624442 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00624442 about?

NCT00624442 is a clinical study titled "A Study of CK-1827452 Infusion in Stable Heart Failure". This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure.

What is the current status of trial NCT00624442?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-04. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00624442?

The interventions under investigation include: CK-1827452 (DRUG).

Who is sponsoring clinical trial NCT00624442?

This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00624442's enrollment target sits among peer trials

45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00624442, the US trial registry maintained by the National Library of Medicine. NCT00624442 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.